SCHEMBL21381804

SCHEMBL21381804

Cc1ccc(S(=O)(=O)ON2CC(c3ccc(OC(F)(F)F)cc3Cl)C2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 3/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
EPHX2 P34913 2/20 0.39
EPHX1 P07099 1/20 0.39
FFAR4 Q5NUL3 1/20 0.37
DPP4 P27487 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
HSD11B1 P28845 1/20 0.35
HTR2A P28223 1/20 0.34
NPBWR1 P48145 1/20 0.34
MCHR1 Q99705 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP14 P50281 1/20 0.34
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21381762 0.88 BCHE (0.41) LIPEBCHEACHEEPHX2EPHX1
SCHEMBL21382020 0.83 DRD2 (0.47) LIPEBCHEACHEMEN1KMT2A
SCHEMBL23211910 0.79 S100A9 (0.39) LIPEEPHX2EPHX1
SCHEMBL21381801 0.77 BCHE (0.41) LIPEBCHEACHEEPHX2EPHX1
SCHEMBL30568009 0.77 BCHE (0.41) LIPEBCHEACHEEPHX2EPHX1
SCHEMBL21381752 0.75 VDR (0.35) LIPEBCHEACHEEPHX2EPHX1
SCHEMBL21381655 0.74 VDR (0.34) LIPEBCHEACHEEPHX2EPHX1
SCHEMBL21381956 0.73 HCRTR1 (0.35) LIPEEPHX2HTR6
SCHEMBL21381814 0.73 HSD11B1 (0.35) LIPEBCHEACHEFFAR4MEN1
SCHEMBL27154212 0.73 BCHE (0.52) LIPEBCHEACHEEPHX2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed
EP-3768684-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-01-27 EP disclosed
WO-2019180185-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885BCHE 186/4885ACHE 170/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC LIPE 6/4885BCHE 186/4885ACHE 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.